Nektar Therapeutics NKTR

NAS: NKTR | ISIN: US6402681083   8/09/2026
75,44 USD (+1,68%)
(+1,68%)   8/09/2026

28 augustus 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

25 augustus 2026 · Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis · Persbericht

13 augustus 2026 · Nektar Therapeutics Announces Second Quarter 2026 Financial Results · Persbericht

29 juli 2026 · Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets · Persbericht

24 juli 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

21 juli 2026 · Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis · Persbericht

26 juni 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

3 juni 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 mei 2026 · Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York · Persbericht

7 mei 2026 · Nektar Therapeutics Reports First Quarter 2026 Financial Results · Persbericht

7 mei 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR · Persbericht

5 mei 2026 · NKTR UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

1 mei 2026 · Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 mei 2026 · Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

1 mei 2026 · Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics and Certain Officers - NKTR · Persbericht

30 april 2026 · NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 · Persbericht

29 april 2026 · Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets · Persbericht

28 april 2026 · Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm · Persbericht

23 april 2026 · Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

22 april 2026 · Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering · Persbericht

Mijn selecties